Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers.Melissa L. Johnson, Himisha Beltran, Adam J. Schoenfeld et al.|Journal of Clinical Oncology|2022Cited by 45
Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC).Johann S. de Bono, Mark N. Stein, Lawrence Fong et al.|Journal of Clinical Oncology|2021Cited by 36